3-phenyllactic acid has been researched along with fingolimod hydrochloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbayir, E; Engevik, MA; Haag, AM; Haidacher, SJ; Hoch, KM; Horvath, TD; Kürtüncü, M; Oezguen, N; Palacio, J; Thapa, S; Türkoğlu, R; Tüzün, E; Versalovic, J; Yılmaz, V | 1 |
1 other study(ies) available for 3-phenyllactic acid and fingolimod hydrochloride
| Article | Year |
|---|---|
Serum 3-phenyllactic acid level is reduced in benign multiple sclerosis and is associated with effector B cell ratios.
Topics: B-Lymphocyte Subsets; Fingolimod Hydrochloride; Humans; Interleukin-4; Multiple Sclerosis | 2022 |